IBTR Risk Estimation
IBTR Risk Estimation is #35 in Medical Paid in Japan and charting in 1 of 24 countries we track.
Updated 27 Sep 2026 · rankings refresh through the day
DeveloperYasuaki Sagara
CategoryMedical
Price500 JPY
Released
Rating★ 5.0 (1)
Version1.5
Age rating17+
First seen by us
25 Sep 2026
25 Sep 2026Rating
5.0 ★
1 ratings
Measured
Best rank now
#35
Medical PaidMeasured
IBTR Risk Estimation on the App Store
App details
App ID
6744888499
Publisher
Yasuaki Sagara
Minimum OS
iOS 16.6+
Content rating
17+
Languages
1
EN
Size
9 MB
Where it ranks now
Every top chart it appears in across 24 countries.
| Country | Charts | Rank |
|---|---|---|
| Japan | MedicalPaid | #35 |
Apps near IBTR Risk Estimation on the chart
Medical Paid, around #35.
Ratings
App Store, worldwide.
Rating
5.0 ★
1 ratings
Measured
Ratings
1
Measured
About IBTR Risk Estimation
This application is a tool to estimate the risk of ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery.
It provides 10-year IBTR risk estimates and treatment effects, based on clinicopathological factors (age, pathological T stage, grade, margin status, lymphovascular invasion, hormone receptor status, HER2 status) and treatment options (radiation therapy, chemotherapy, endocrine therapy, anti-HER2 therapy). The application is available for both iPhone and iPad.
The tool was developed using a Cox proportional hazards model from a multicenter cohort of 8,938 patients and calibrated with treatment effects from the EBCTCG meta-analysis. It is designed for use in shared decision-making between patients and clinicians, as well as for educational purposes. The development methodology was presented at the 2025 ASCO Annual Meeting (Abstract No. 575) and published in JCO Clinical Cancer Informatics (Sagara et al., 2025). For further details, please refer to the publication.
Disclaimer
This application is intended for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions should always be made in consultation with the treating physician. The developers assume no legal responsibility for any outcomes resulting from the use of this application.
It provides 10-year IBTR risk estimates and treatment effects, based on clinicopathological factors (age, pathological T stage, grade, margin status, lymphovascular invasion, hormone receptor status, HER2 status) and treatment options (radiation therapy, chemotherapy, endocrine therapy, anti-HER2 therapy). The application is available for both iPhone and iPad.
The tool was developed using a Cox proportional hazards model from a multicenter cohort of 8,938 patients and calibrated with treatment effects from the EBCTCG meta-analysis. It is designed for use in shared decision-making between patients and clinicians, as well as for educational purposes. The development methodology was presented at the 2025 ASCO Annual Meeting (Abstract No. 575) and published in JCO Clinical Cancer Informatics (Sagara et al., 2025). For further details, please refer to the publication.
Disclaimer
This application is intended for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions should always be made in consultation with the treating physician. The developers assume no legal responsibility for any outcomes resulting from the use of this application.
Latest updates
1.5
Updated the Age Rating settings.